• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ECOG 体能状态评分在预测上尿路上皮癌患者预后中的作用:一项国际研究。

Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: an international study.

机构信息

Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Autónoma de Madrid, Spain.

出版信息

BJU Int. 2012 Apr;109(8):1155-61. doi: 10.1111/j.1464-410X.2011.10479.x. Epub 2011 Aug 24.

DOI:10.1111/j.1464-410X.2011.10479.x
PMID:21883847
Abstract

OBJECTIVE

To evaluate the prognostic role of ECOG Performance status (ECOG-PS) in a large multi-institutional international cohort of patients treated with radical nephroureterectomy for upper tract urothelial carcinoma.

MATERIALS AND METHODS

Data of 427 patients treated with radical nephroureterectomy at five international institutions in Asia, Europe and Northern America were collected retrospectively from 1987 to 2008. Logistic and Cox regression models were used for univariable and multivariable analyses.

RESULTS

ECOG-PS was 0 in 272 of 427 (64%) patients. The median follow-up of the whole cohort was 32 months. The five-year recurrence-free (RFS), cancer-specific (CSS) and overall (OS) survival estimates were 71.7%, 74.9% and 68.5%, respectively, in patients with ECOG-PS 0 compared with 60.1%, 67.8%, and 51.4% respectively, in patients with ECOG-PS ≥1 (P value 0.08 for RFS, 0.43 for CSS, and <0.001 for OS, respectively). On multivariable Cox regression analyses, ECOG-PS was not an independent predictor of either RFS (hazard ratio 1.4; P = 0.107) or CSS (hazard ratio 1.2; P = 0.426) but was an independent predictor of OS (hazard ratio 1.5; P = 0.03).

CONCLUSIONS

In this large multicentre international study, ECOG-PS was not significantly associated with RFS and CSS. Conversely we find a strong association with survival 1-month after surgery and OS. Further research is needed to ascertain the additive prognostic role of ECOG-PS in well-designed prospective multicentre studies.

摘要

目的

评估 ECOG 体能状态(ECOG-PS)在接受根治性肾输尿管切除术治疗上尿路上皮癌的大型多机构国际队列中的预后作用。

材料与方法

回顾性收集了 1987 年至 2008 年 5 个国际机构(亚洲、欧洲和北美)接受根治性肾输尿管切除术的 427 例患者的数据。使用逻辑和 Cox 回归模型进行单变量和多变量分析。

结果

427 例患者中,ECOG-PS 为 0 的有 272 例(64%)。整个队列的中位随访时间为 32 个月。ECOG-PS 为 0 的患者 5 年无复发生存(RFS)、癌症特异性(CSS)和总生存(OS)估计值分别为 71.7%、74.9%和 68.5%,ECOG-PS≥1 的患者分别为 60.1%、67.8%和 51.4%(P 值分别为 0.08 用于 RFS、0.43 用于 CSS 和<0.001 用于 OS)。多变量 Cox 回归分析显示,ECOG-PS 不是 RFS(危险比 1.4;P = 0.107)或 CSS(危险比 1.2;P = 0.426)的独立预测因素,但与 OS(危险比 1.5;P = 0.03)独立相关。

结论

在这项大型多中心国际研究中,ECOG-PS 与 RFS 和 CSS 无显著相关性。相反,我们发现它与术后 1 个月的生存和 OS 有很强的相关性。需要进一步的研究来确定 ECOG-PS 在设计良好的前瞻性多中心研究中的附加预后作用。

相似文献

1
Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: an international study.ECOG 体能状态评分在预测上尿路上皮癌患者预后中的作用:一项国际研究。
BJU Int. 2012 Apr;109(8):1155-61. doi: 10.1111/j.1464-410X.2011.10479.x. Epub 2011 Aug 24.
2
Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma.宏观无蒂肿瘤形态是具有侵袭性的上尿路尿路上皮癌的一种病理特征。
Urol Oncol. 2012 Sep;30(5):666-72. doi: 10.1016/j.urolonc.2010.07.010. Epub 2010 Oct 8.
3
Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.预测根治性肾输尿管切除术治疗上尿路上皮癌的临床结局。
Eur Urol. 2012 Apr;61(4):818-25. doi: 10.1016/j.eururo.2012.01.021. Epub 2012 Jan 23.
4
Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy.接受根治性肾输尿管切除术治疗的上尿路尿路上皮癌患者合并症与预测肿瘤学结局的性能指标的比较分析。
Urol Oncol. 2014 Nov;32(8):1141-50. doi: 10.1016/j.urolonc.2014.04.008. Epub 2014 May 22.
5
Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy.在上尿路尿路上皮癌患者接受肾输尿管切除术和膀胱袖状切除术治疗中,肿瘤位置与多灶性的影响:无围手术期化疗的同质系列。
BJU Int. 2012 Jul;110(2 Pt 2):E7-13. doi: 10.1111/j.1464-410X.2011.10792.x. Epub 2011 Dec 16.
6
Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration.开放和腹腔镜根治性肾输尿管切除术的肿瘤学结果比较:来自加拿大上尿路协作组的结果。
BJU Int. 2013 Oct;112(6):791-7. doi: 10.1111/j.1464-410X.2012.11474.x. Epub 2012 Nov 13.
7
Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort.腹腔镜与开放根治性肾输尿管切除术的肿瘤学结果:国际队列研究结果。
BJU Int. 2011 Aug;108(3):406-12. doi: 10.1111/j.1464-410X.2010.09826.x. Epub 2010 Nov 15.
8
Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract: impact on survival.腹膜后淋巴结清扫术(RPLD)联合肾输尿管切除术治疗上尿路浸润性移行细胞癌(TCC):对生存率的影响
Eur Urol. 2007 Nov;52(5):1414-8. doi: 10.1016/j.eururo.2007.04.070. Epub 2007 May 2.
9
Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients.同时性原位癌作为上尿路上皮癌复发和生存的独立预后参数:772 例患者的多中心分析。
World J Urol. 2011 Aug;29(4):487-94. doi: 10.1007/s00345-011-0645-8. Epub 2011 Jan 20.
10
The role of American Society of Anesthesiologists scores in predicting urothelial carcinoma of the upper urinary tract outcome after radical nephroureterectomy: results from a national multi-institutional collaborative study.美国麻醉医师协会评分在预测根治性肾输尿管切除术治疗上尿路上皮癌结局中的作用:来自全国多机构合作研究的结果。
BJU Int. 2012 Dec;110(11 Pt C):E1035-40. doi: 10.1111/j.1464-410X.2012.11195.x. Epub 2012 May 8.

引用本文的文献

1
Preoperative ECOG performance status as a predictor of outcomes in upper tract urothelial cancer surgery.术前东部肿瘤协作组(ECOG)体能状态作为上尿路尿路上皮癌手术预后的预测指标。
Sci Rep. 2025 Mar 26;15(1):10356. doi: 10.1038/s41598-025-95128-1.
2
A Multi-Institutional Natural Language Processing Pipeline to Extract Performance Status From Electronic Health Records.多机构自然语言处理管道从电子健康记录中提取表现状态。
Cancer Control. 2024 Jan-Dec;31:10732748241279518. doi: 10.1177/10732748241279518.
3
Does age impact clinical outcomes of radical nephroureterectomy in the elderly?-results from a multicenter retrospective study.
年龄对老年患者根治性肾输尿管切除术的临床结局有影响吗?——一项多中心回顾性研究的结果
Transl Androl Urol. 2024 May 31;13(5):688-698. doi: 10.21037/tau-24-37. Epub 2024 May 22.
4
Upper Tract Urothelial Carcinoma (UTUC) Diagnosis and Risk Stratification: A Comprehensive Review.上尿路尿路上皮癌(UTUC)的诊断与风险分层:综述
Cancers (Basel). 2023 Oct 14;15(20):4987. doi: 10.3390/cancers15204987.
5
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.吉西他滨和顺铂新辅助化疗治疗高级上尿路尿路上皮癌的多中心 II 期临床试验。
J Clin Oncol. 2023 Mar 10;41(8):1618-1625. doi: 10.1200/JCO.22.00763. Epub 2023 Jan 5.
6
Prognostic Value of Comorbidity for Patients with Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy.根治性肾输尿管切除术后上尿路尿路上皮癌患者合并症的预后价值
Cancers (Basel). 2022 Mar 12;14(6):1466. doi: 10.3390/cancers14061466.
7
The influence of acute kidney disease on the clinical outcomes of patients who received cisplatin, carboplatin, and oxaliplatin.急性肾疾病对接受顺铂、卡铂和奥沙利铂治疗患者临床结局的影响。
Health Sci Rep. 2022 Jan 12;5(1):e479. doi: 10.1002/hsr2.479. eCollection 2022 Mar.
8
Risk stratification for upper tract urinary carcinoma.上尿路尿路上皮癌的风险分层
Transl Androl Urol. 2020 Aug;9(4):1799-1808. doi: 10.21037/tau.2019.12.21.
9
Incidence and preoperative predictors for major complications following radical nephroureterectomy.根治性肾输尿管切除术术后主要并发症的发生率及术前预测因素
Transl Androl Urol. 2020 Aug;9(4):1786-1793. doi: 10.21037/tau.2020.01.22.
10
Validation of Hyponatremia as a Prognostic Predictor in Multiregional Upper Tract Urothelial Carcinoma.低钠血症作为多区域上尿路尿路上皮癌预后预测指标的验证
J Clin Med. 2020 Apr 23;9(4):1218. doi: 10.3390/jcm9041218.